News

As part of the agreement, Shire will make an initial upfront payment to Boston Children’s and also fund selected research programs. The duo will primarily focus on treatment

Incorporating a preconfigured system that answers various pharma-specific use cases, the Planisware Prime for Pharma solution helps clients to gain real-time visibility into their portfolio and resources. The

The company will use the finance to expand its comprehensive suite of software products and services. Horizon president Gerald Michaud said, "We are pleased to provide this venture

The second-generation anticancer agent with a dual-mechanism vascular disrupting feature integrates vascular disrupting activity and direct cytotoxicity. With the issuance of orphan drug designation, the company gains market

The terms of the deal that also involves marketing of the extended topical generic product were not revealed. Impax Laboratories president and CEO Larry Hsu said, "In just

Aubagio, which has anti-inflammatory properties, is expected to minimize activated lymphocyte count in the central nervous system. Genzyme multiple sclerosis head Bill Sibold said with the TGA approval

According to the study data, the AB103 administered patients demonstrated a meaningful improvement across multiple endpoints compared to placebo. The University of Washington Harborview Medical Center professor of

The injectable sulfactam antibiotic has the potential to target clinically relevant gram-negative bacteria resistant to multiple drugs including Pseudomonas or Acinetobacter species. Basilea chief medical officer Prof. Achim

Under the collaboration, Ablynx will provide access to novel Nanobodies, generated using proprietary technology platform, and Algeta will provide access to chelation and conjugation technologies, as well as